Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection

作者: Barbara Reinhardt , Robert Jaspert , Matthias Niedrig , Christian Kostner , Johanna L'age-Stehr

DOI: 10.1002/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B

关键词:

摘要: To monitor early and late events of immune system activation after primary secondary flavivirus infection, 17 healthy persons were vaccinated with the standard 17D vaccine virus strain yellow fever (YF). Twelve these had not received YF previously 5 been once at least 10 years before. Viremia various parameters humoral cellular followed daily for 7 days weekly thereafter. was detected by reverse transcriptase-polymerase chain reaction in all 12 first-time vaccinees beginning from second to sixth day vaccination; most tested positive between fourth day. Infectious using a plaque forming assay serum vaccinees. As first activation, neopterin β2-microglobulin markedly increased 2 6 postvaccination. In parallel viremia, circulating CD8+ T-cells significantly increased, peak levels vaccination, indicating an system. Neither viremia nor significant changes markers observed five revaccinated persons. Neutralizing antibodies directed against developed within weeks vaccination. No correlation found extent titer neutralizing antibodies. Revaccination minor transient increase High titers persisted J. Med. Virol. 56: 159–167, 1998. © 1998 Wiley-Liss, Inc.

参考文章(27)
E. Frederick Wheelock, William A. Sibley, CIRCULATING VIRUS, INTERFERON AND ANTIBODY AFTER VACCINATION WITH THE 17-D STRAIN OF YELLOW-FEVER VIRUS. The New England Journal of Medicine. ,vol. 273, pp. 194- 198 ,(1965) , 10.1056/NEJM196507222730404
J S Porterfield, A T De Madrid, A simple micro-culture method for the study of group B arboviruses. Bulletin of The World Health Organization. ,vol. 40, pp. 113- 121 ,(1969)
Groot H, Riberiro Rb, Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bulletin of The World Health Organization. ,vol. 27, pp. 699- 707 ,(1962)
Thomas P. Monath, Pathobiology of the Flaviviruses Springer, Boston, MA. pp. 375- 440 ,(1986) , 10.1007/978-1-4757-0785-4_12
A L Rothman, I Kurane, C J Lai, M Bray, B Falgout, R Men, F A Ennis, Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes. Journal of Virology. ,vol. 67, pp. 801- 806 ,(1993) , 10.1128/JVI.67.2.801-806.1993
J J Schlesinger, M W Brandriss, C B Cropp, T P Monath, Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. Journal of Virology. ,vol. 60, pp. 1153- 1155 ,(1986) , 10.1128/JVI.60.3.1153-1155.1986
T P Monath, K Murphy, W G Downs, J D Poland, C H Calisher, Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine Bulletin of The World Health Organization. ,vol. 59, pp. 895- 900 ,(1981)
Max Theiler, Hugh H. Smith, THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION Journal of Experimental Medicine. ,vol. 65, pp. 787- 800 ,(1937) , 10.1084/JEM.65.6.787
Claudia N. Duarte dos Santos, Paulo R. Post, Ricardo Carvalho, Idevaldo I. Ferreira, Charles M. Rice, Ricardo Galler, Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213 Virus Research. ,vol. 35, pp. 35- 41 ,(1995) , 10.1016/0168-1702(94)00076-O